KLK3 and neoplasm: Patients classified as intermediate- or high-risk based on clinical tumor category, biopsy Gleason score, and pretreatment prostate-specific antigen (PSA) levels have a significantly elevated risk of experiencing metastatic progression compared with low-risk PCa.